RxDoctor Payments Data

Enrique Infante, MD

Obstetrics & Gynecology · Elkhart, INNPI 1194707117

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,362 of the $41,128 with a category attached, or 64.1%. 35 manufacturers reported payments, led by Johnson & Johnson at 53.7% of the total. 2025 is the largest year on record at $25,582, 6.2 times the $4,097 reported in 2019. Among obstetrics & gynecology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,128in general payments, 2019–2025

Across 165 payments — averaging $249.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$22K
  • Medical Device Business Services, Inc.$6K
  • Intuitive Surgical$6K
  • Avanos Medical$3K
  • Acessa Health Inc.$2K
  • Gynesonics, Inc.$342
  • plus $2K from 29 others

What the payments were for

  • Consulting fees$26,36264%
  • Travel & lodging$6,94617%
  • Food & beverage$4,77112%
  • Education$3,0007%
  • Gifts$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,128 in reported general payments places this provider in the 95th percentile of 743 obstetrics & gynecology providers in Indiana.

See all obstetrics & gynecology providers in Indiana

Medicare billing

Part B allowed, 2024
$18,942
Medicare patients
59
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$8,996
PremarinEstrogens, Conjugated22$6,781
PremproEstrogen,con/M-Progest Acet14$6,011
Estradiol58$3,368
Clobetasol Propionate24$1,218
Venlafaxine Hcl ErVenlafaxine Hcl16$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Prempro$15$12,79236 claims
Astellas Pharma US IncMyrbetriq$102$8,99611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 743 obstetrics & gynecology providers in Indiana.

Other obstetrics & gynecology in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →